FDA Licenses First-Ever Freeze-Dried Plasma Product in the U.S.

FDA Licenses First Freeze-Dried Plasma Product

The U.S. Food and Drug Administration (FDA) has licensed Ezplaz Freeze Dried Plasma (FDP), making it the first freeze-dried plasma product approved for use in the United States. This product is intended for transfusion in adult patients experiencing life-threatening bleeding or plasma deficiency when conventional frozen plasma products are unavailable. Ezplaz offers significant advantages, including room-temperature stability, rapid reconstitution, and durable plastic packaging, making it a crucial option for emergency and remote settings like combat zones, disaster areas, and rural environments, addressing a critical unmet medical need, particularly for military personnel.

• Ezplaz FDP is a lyophilized plasma product derived from a single unit of fresh frozen plasma, available in Group AB and Group A with low-titer anti-B blood types. Its key features include room-temperature stability, resilience to temperature fluctuations, and rapid reconstitution. Packaged in a plastic bag, it minimizes breakage risk during transport, making it uniquely suited for austere environments such as combat zones, remote areas, and disaster response settings where traditional hospital infrastructure is limited.
• The product is specifically indicated for transfusion in adults when plasma is required and other plasma products are not available, including bleeding patients, those needing massive transfusion, or certain patients on warfarin who are bleeding. The FDA has determined that the benefits of Ezplaz transfusion outweigh its risks, and its safety profile is consistent with other plasma products used for transfusion, with healthcare providers advised to review full prescribing information.
• The licensure of Ezplaz was facilitated by Public Law 115-92, enacted in December 2017, which authorized a DoD-FDA collaboration to expedite the development and review of products for serious or life-threatening conditions affecting American military personnel. This collaboration led to the FDA issuing guidance in 2019 to assist manufacturers in developing dried plasma products, showcasing how innovation can advance alongside rigorous scientific review to expand treatment options.
• The biologics license for Ezplaz was granted to Vascular Solutions, LLC, a subsidiary of Teleflex. This milestone action addresses an important unmet medical need, particularly for military personnel and others who may be far from traditional hospital infrastructure, by providing faster access to plasma in critical situations.

Overcoming Limitations in Plasma Transfusion for Life-Threatening Bleeding

Current management of life-threatening bleeding and plasma deficiency remains constrained by resource limitations, diagnostic gaps, and an incomplete evidence base guiding transfusion strategy. While blood component therapy and massive transfusion protocols remain the cornerstone of treatment, significant uncertainties persist around optimal ratios, timing, and long-term safety. These limitations are compounded by a lack of pediatric-specific data and disparities in resource availability across healthcare settings.

• Transfusion-associated risks: Red blood cell and plasma transfusion have been linked to post-injury infection, multiple organ failure, transfusion-associated circulatory overload (TACO), transfusion-related acute lung injury (TRALI), and thromboembolic events; rampant red cell infusion has also shown detrimental effects on short- and long-term survival.

• Uncertain optimal transfusion ratios and thresholds: Evidence is insufficient to definitively recommend a 1:1:1 over 1:1:2 FFP:platelet:RBC ratio, or standard care, in adult massive transfusion; higher ratios increase FFP and platelet use without clear mortality or morbidity benefit. The critical minimum fibrinogen concentration for hemostasis also remains debated, and optimal dosing/timing of blood components is unknown.

• Limitations of diagnostic and monitoring tools: Conventional coagulation tests (PT, aPTT) poorly predict bleeding risk and fail to adequately guide transfusion therapy in critically ill patients, though viscoelastic tests (TEG/ROTEM) offer bedside, whole-blood functional assessment and are gaining traction as diagnostic and transfusion-guiding tools.

• Resource and infrastructure constraints: Massive transfusion requires extensive blood-banking resources and is associated with high mortality; in low- and middle-income countries, limited access to blood products, hemostatic medications, and hematologic expertise significantly compromises hemorrhage control, particularly in obstetric emergencies.

• Gaps in understanding bleeding vs. dying from bleeding: A major clinical challenge lies in distinguishing patients with true refractory coagulopathy from those with unsurvivable injuries — notably, only 2% of hospital deaths post-injury are attributed to refractory coagulopathy, with most bleeding-related deaths occurring because patients are dying, not dying because they are bleeding.

• Lack of proven glycocalyx-targeted therapies: No proven therapies currently exist for preventing or treating endothelial glycocalyx degradation; while plasma components (e.g., sphingosine-1-phosphate, antithrombin, adiponectin) show exploratory promise in restoring vascular homeostasis, this evidence remains non-clinical and preliminary.

• Guideline variability and trial feasibility: Inconsistent diagnostic criteria, blood-loss assessment methods, and escalation strategies persist across postpartum hemorrhage guidelines, and conducting randomized controlled trials in critically bleeding populations remains inherently challenging, limiting the strength of available evidence.

• Pediatric evidence gap: Much of the research underpinning life-saving adult interventions—including massive transfusion protocols and antifibrinolytic use—has not been validated in pediatric populations, leaving transfusion strategies in children controversial and in need of dedicated investigation.

• Absence of immune-modulating therapies: No clinically effective treatments currently exist to stabilize the immune response to hemorrhage or restore homeostatic conditions, underscoring a critical unmet need for further therapeutic development.

Reshaping the Treatment Landscape for Life-Threatening Bleeding

Recent advancements in managing life-threatening bleeding have centered on the development and strategic use of specific reversal agents and novel therapeutic approaches. For direct oral anticoagulant (DOAC)-associated bleeding, idarucizumab and andexanet alfa have been approved to reverse dabigatran and factor Xa inhibitors (apixaban, rivaroxaban), respectively. Clinical experience with idarucizumab highlights the potential for dabigatran concentration rebound, particularly in patients with high baseline drug levels or renal impairment, suggesting a need for post-administration monitoring and possible repeat dosing. In emergencies where specific agents are unavailable, non-specific prothrombin complex concentrates (PCCs) remain a viable option. The therapeutic arsenal is also expanding to address bleeding from other agents, with therapeutic plasma exchange (TPE) showing potential as an effective option for removing circulating ticagrelor in refractory cases. For specific plasma deficiencies, targeted combination therapies are emerging, such as very-low-dose decitabine with recombinant human thrombopoietin, which has demonstrated efficacy in improving platelet counts and achieving transfusion independence in patients with lower-risk myelodysplastic syndrome.

The role of established agents and large-scale resuscitation strategies continues to be refined through major clinical trials and updated guidelines. The ongoing TROOP trial (NCT05638581), a large multicenter study, is currently evaluating whether Low-Titer Group O Whole Blood (LTOWB) is superior or non-inferior to standard component therapy for resuscitating critically injured patients, with 6-hour mortality as the primary outcome. Simultaneously, the use of tranexamic acid (TXA) is being optimized across various indications. While high-dose TXA (≥2 g) may reduce transfusion requirements, its effect on mortality remains uncertain. Recent evidence suggests that for hematological disorders, TXA likely offers little to no difference in preventing clinically significant bleeding. In obstetric settings, prophylactic TXA for cesarean delivery did not reduce mean blood loss but did lower the incidence of severe hemorrhage (>2000 mL) and D-dimer levels, while updated guidelines strongly support its early use as an adjunct to uterotonics.

Management strategies are also becoming more tailored to specific patient populations and clinical contexts based on recent evidence. In pelvic fracture patients requiring trans-arterial embolization, data suggest that pre-procedural blood transfusions exceeding 2 units are associated with a higher incidence of coagulopathy and other adverse outcomes, underscoring the importance of achieving early hemostasis. For liver transplant recipients, total parenteral nutrition with a mixed lipid emulsion (SMOFlipid) has been shown to improve nutritional status and post-operative platelet counts without increasing the risk of coagulopathy. Furthermore, novel strategies are being explored for unique scenarios, such as the use of modified glucose-insulin-potassium (GIK) therapy to ameliorate coagulopathy in hemorrhage-induced traumatic cardiac arrest and the management of acquired coagulopathy from immune checkpoint inhibitors with glucocorticoids and factor support.